Amgen launches the first US Humira biosimilar at two different list prices

The bizarre dynamics of the US prescription drug market were on full display once again this morning as Amgen announced that it would launch the first US biosimilar for Humira, the best-selling drug of all time, at two completely different list prices. One price for Amgen’s Amjevita (adalimumab-atto) will be…